POLYMICROBIAL ASSOCIATIONS IN THE ETIOLOGY OF INFLAMMATORY DISEASES OF THE FEMALE GENITAL ORGANS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To assess the role of polymicrobial associations in the genesis of inflammatory diseases of the female genital organs and to determine the most rational approaches to diagnosis and treatment. Material and methods. The materials of the World Health Organization, the Cochrane Society, the guidelines of leading professional societies, and clinical trials published on official websites and in open access were analyzed. Results. There was information on the frequency of female genital tract inflammatory diseases caused by microbial combinations, as well as the established facts on resistance to antimicrobial agents, recommendations for their diagnosis and treatment, by indicating the strength of the evidence and convincingness of recommendations. Conclusion. The recent changes in the epidemiology of inflammatory diseases, the prevalence of polymicrobial associations in their etiology, and the increasing microbial resistance require new approaches to the treatment and prevention of sexually transmitted infections and diseases accompanied by abnormal vaginal discharge.

Full Text

Restricted Access

About the authors

Galina B. Dikke

Peoples' Friendship University of Russia

Email: galadikke@yandex.ru
Honoured Science and Education, MD, professor of obstetrics, gynecology and reproductive medicine, faculty of continuing medical education Moscow 117198, Miklukho-Maklaya str. 8, Russia

References

  1. Хрянин А.А. Бактериальный вагиноз. Новые представления о микробном биосоциуме и возможности лечения. Медицинский совет. 2014; 17: 128
  2. Герасимова О.П. Клинико-морфологическая оценка эффективности прегравидарной подготовки женщин, перенесших неразвивающуюся беременность: автореф. дисс.. канд. мед. наук. М.; 2014. 18с.
  3. Report on global sexually transmitted infection surveillance 2015. WHO; 2016. 54р.
  4. Swidsinski A., Mendling W., Loening-Baucke V. et al. Adherent biofilms in bacterial vaginosis. Obstet. Gynecol. 2005; 106: 1013-23.
  5. Creatsas G., Deligeoroglou E. Microbial ecology of the lower genital tract in women with sexually transmitted diseases. J. Med. Microbiol. 2012; 61: 1347-51.
  6. Рахматулина М.Р., Цой Е.Г. Современные показатели резистентности грибов рода кандида к антимикотическим препаратам. Фарматека. 2017; Дерматология. Спец. вып.: 22-5.
  7. Tansarli G.S., Kostaras E.K., Athanasiou S., Falagas M.E. Prevalence and treatment of aerobic vaginitis among non-pregnant women: evaluation of the evidence for an underestimated clinical entity. Eur. J. Clin. Microbiol. Infect. Dis. 2013; 32(8): 977-84.
  8. Sexually Transmitted Diseases Treatment Guidelines. CDC; 2015. Available at: https://www.cdc.gov
  9. Mugo N., Dadabhai S.S., Bunnell R. et al. Prevalence of herpes simplex virus type 2 infection, human immunodeficiency virus/herpes simplex virus type 2 coinfection, and associated risk factors in a national, population-based survey in Kenya. Sex. Transm. Dis. 2011; 38(11): 1059-66.
  10. Marrazzo J.M., Wiesenfeld H.C., Murray P.J. et al. Risk factors for cervicitis among women with bacterial vaginosis. J. Infect. Dis. 2006; 193(5): 617-24.
  11. Ljubin-Sternak S., Mestrovicc T. Chlamydia trachomatis and Genital Mycoplasmas: Pathogens with an impact. Hum. Rep. Health J. Pat. 2014; 183167.
  12. Clarke L.M., Duerr A., Yeung K.H. et al. Recovery of cytomegalovirus and herpes simplex virus from upper and lower genital tract specimens obtained from women with pelvic inflammatory disease. J. Infect. Dis. 1997; 176(1): 286-8.
  13. Ness R.B., Kip K.E., Hillier S.L. et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am. J. Epidemiol. 2005; 162(6): 585-90.
  14. Johnson H.L., Ghanem K.G., Zenilman J.M., Erbelding E.J. Sexually transmitted infections and adverse pregnancy outcomes among women attending inner city public sexually transmitted diseases clinics. Sex. Transm. Dis. 2011; 38(3): 167-71.
  15. Fan A., Yue Y., Geng N. et al. Aerobic vaginitis and mixed infections: comparison of clinical and laboratory findings. Arch. Gynecol. Obstet. 2013; 287(2): 329-35.
  16. Poljak M., Seme K., Maver P.J. et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine. 2013; 31 (7): 59-70.
  17. Walker C.K., Sweet R.L. Gonorrhea infection in women: prevalence, effects, screening, and management. Int. J. Womens Health. 2011; 3: 197-206.
  18. Wiesenfeld H.C., Hillier S.L., Krohn M.A. et al. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin. Infect. Dis. 2003; 36(5): 663-8.
  19. Cherpes T.L., Meyn L.A., Krohn M.A. et al. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin. Infect. Dis. 2003; 37(3): 319-25.
  20. Cu-Uvin S., Hogan J.W., Caliendo A.M. et al. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin. Infect. Dis. 2001; 33(6): 894-6.
  21. Atashili J., Poole C., Ndumbe P.M. et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008; 22(12): 1493-501.
  22. Bautista C.T., Wurapa E., Sateren W.B. et al. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil. Med.Res. 2016; 3: 4.
  23. Mutagoma M., Remera E., Sebuhoro D. et al. The prevalence of syphilis infection and its associated factors in the general population of Rwanda: A National Household-Based Survey. J. Sex. Transm. Dis. 2016; 2016: 4980417.
  24. Grueva E., Borisov I. The role of chlamydia trachomatis and some other associated microorganisms in endocervicitis. Akush. Ginekol. (Sofiia). 2006; 45(5): 32-5.
  25. Guidelines for the treatment of Chlamydia trachomatis. WHO’ 2016. 47р.
  26. Федеральные клинические рекомендации по ведению больных хламидийной инфекцией. 2015. Акушерство и гинекология. 2016; 4: 57-64.
  27. Sorvillo F., Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet. 1998; 351(9097): 213-4.
  28. Guidelines for the treatment of Neisseria gonorrhoeae. WHO; 2016. 55р.
  29. Guidelines for the treatment of Genital Herpes Simplex Virus. WHO; 2016. 47р.
  30. Guidelines for the treatment of Treponema pallidum. WHO; 2016. 51р.
  31. Федеральные клинические рекомендации по ведению больных урогенитальными заболеваниями, вызванными Mycoplasma genitalium. 2015. Акушерство и гинекология. 2016; 4: 64-70.
  32. Федеральные клинические рекомендации по ведению больных урогенитальным трихомониазом. М.; 2013. 14с
  33. Федеральные клинические рекомендации по ведению больных бактериальным вагинозом. 2015. Акушерство и гинекология. 2016; 4: 43-50
  34. Swidsinski A., Verstraelen H., Loening-Baucke V. et al. Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. PLoS One. 2013; 8(1): e53997.
  35. Koumans E.H., Markowitz L.E., Hogan V. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin. Infect. Dis. 2002; 35(2): 152-72.
  36. Федеральные клинические рекомендации по ведению больных урогенитальным кандидозом. 2015. Акушерство и гинекология. 2016; 4: 50-7.
  37. Gottschick C., Szafranski S.P., Kunze B. et al. Screening of compounds against Gardnerella vaginalis biofilms. PLoS One. 2016; 11(4): e0154086.
  38. McMillan A., Dell M., Zellar M.P., Cribby S., Martz S., Hong E. et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf. B Biointerfaces. 2011; 86(1): 58-64.
  39. Mania-Pramanik J., Kerkar S.C., Salvi V.S. Bacterial vaginosis: a cause of infertility? Int. J. STD AIDS. 2009; 20: 778-781.
  40. Sherrardl J., Donders G., White D., Jensen J.S. European (IUSTI/WHO) guideline on the management of vaginal discharge. 2011. 23р. Available at: http://www.iusti.org/
  41. Burton J.P., Devillard E., Cadieux P.A. et al. Detection of Atopobium vaginae in postmenopausal women by cultivationindependent methods warrants further investigation. J. Clin. Microbiol. 2004; 42: 1829-31.
  42. Beigi R.H., Austin M.N., Meyn L.A. et al. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am. J. Obstet. Gynecol. 2004; 191(4): 1124-9.
  43. Truter I., Graz M. Bacterial vaginosis: Literature review of treatment options with specific emphasis on non-antibiotic treatment. Review. Afr. J. Pharm. Pharmacol. 2013; 7(48): 3060-7.
  44. Geissdorfer W., Bohmer C., Pelz K. et al. Tubo-ovarian abscess caused by Atopobium vaginae following transvaginal oocyte recovery. J. Clin. Microbiol. 2003; 41: 2788-90.
  45. Сарвилина И.В., Кузьмина Н. Новое комбинированное топическое лекарственное средство для лечения хронического вульвовагинита. Врач. 2015; 9: 74-80.
  46. Aral S.O. Utility and delivery of behavioural interventions to prevent sexually transmitted infections. Sex. Transm. Infect. 2011; 87(2): 31-3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies